GlassScriptPhysician profile
Jacqueline D Tran
NPI 1831220102
$12,054.12
in general payments reported to CMS, 2019-2025
48 companies · $2,905 in 2025
The $2,905 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,665 · 2022: $1,691 · 2023: $2,938 · 2024: $2,855 · 2025: $2,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,697 · Travel and Lodging: $1.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,696.80 |
| Travel and Lodging | $1.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,043.91 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,180.36 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $975.19 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $812.54 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $632.94 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $579.16 | 2021-2025 | Jardiance |
| Gilead Sciences, INC. | $462.20 | 2021-2025 | Vemlidy |
| Genzyme Corporation | $406.67 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $380.02 | 2023-2025 | Ingrezza |
| Glaxosmithkline, LLC. | $323.07 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $300.96 | 2022-2025 | Dupixent, Evkeeza, Libtayo |
| Lilly USA, LLC | $287.35 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Nestle Healthcare Nutrition INC. | $271.40 | 2021-2022 | |
| Corcept Therapeutics | $252.01 | 2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $203.44 | 2023-2024 | Nuzyra |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $198.61 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $193.32 | 2022-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $181.89 | 2021-2023 | Xarelto, Spravato |
| Dexcom, INC. | $176.72 | 2024-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $160.74 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.47 | 2023 | Trulance, Xifaxan |
| Agios Pharmaceuticals, INC. | $143.97 | 2024 | Pyrukynd |
| Madrigal Pharmaceuticals | $142.72 | 2025 | Rezdiffra |
| Idorsia Pharmaceuticals US INC | $134.17 | 2023 | Quviviq |
| Merz North America, INC. | $132.98 | 2023-2024 | Xeomin |
| Ibsa Pharma INC. | $127.62 | 2023 | Licart, Tirosint, Licart |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2023 | |
| Sumitomo Pharma America, INC. | $124.27 | 2025 | Myfembree |
| Aimmune Therapeutics, INC. | $123.86 | 2024 | |
| Viatris Specialty LLC | $120.13 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $105.44 | 2022 | |
| Cequr Corporation | $90.48 | 2023 | Cequr Simplicity |
| Amarin Pharma, INC. | $88.82 | 2021-2022 | |
| Almatica Pharma LLC | $49.05 | 2024-2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $46.30 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Dynavax Technologies Corporation | $39.32 | 2021-2022 | |
| Mylan Specialty L.P. | $35.17 | 2021 | |
| Shield Therapeutics INC | $35.14 | 2024 | |
| Intra-Sana Laboratories | $34.80 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Insulet Corporation | $31.56 | 2025 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $26.21 | 2025 | Rexulti |
| Almirall LLC | $24.79 | 2021 | |
| Eisai INC. | $22.18 | 2022 | |
| Zimmer Biomet Holdings, INC. | $21.98 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Redhill Biopharma INC. | $18.17 | 2023 | Talicia, Movantik, Aemcolo |
| Vyne Pharmaceuticals INC. | $17.10 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.85 | 2021 | |
| Evofem Biosciences, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.